A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

Study Summary

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

Conditions

Solid Tumor Epithelial Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer

Interventions / Drugs

Azenosertib Carboplatin Pegylated liposomal doxorubicin Paclitaxel Gemcitabine Bevacizumab

View on ClinicalTrials.gov ↗

Sponsor

ZNTL

Zentalis Pharmaceuticals

Oncology

D36/100

Study Details

Enrollment172 participants

Primary Completion—

Lead SponsorK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Data Retrieved2026-04-11 04:32:15.024591+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.